When does Longeveron report earnings and why does it matter for LGVN stock?

Longeveron reports after market on 12 Mar 2026; the report may disclose trial progress, cash runway, and milestones that can move LGVN stock sharply because the company is clinical-stage and valuation is catalyst-driven.

What are the main valuation metrics for LGVN stock to watch?

Key metrics include **EPS -$0.98**, **Price/Book ~0.99**, **Price/Sales ~7.98**, cash per share **$0.50**, and current ratio **2.09**; these measure profitability, leverage, and short-term liquidity for LGVN stock.

How should volatile moves in LGVN stock be managed around earnings?

Use position sizing and stop limits; consider event-driven trades or optionality instead of large directional exposure because LGVN stock can gap on binary clinical news and has limited analyst coverage.

What does Meyka AI forecast for LGVN stock and how reliable is it?

Meyka AI's forecast model projects a monthly price of **$0.36** for LGVN stock, implying a **-62.37%** move vs current price **$0.9558**. Forecasts are model-based projections and not guarantees.

US Stocks

LGVN Longeveron (NASDAQ) +97.64% intraday 10 Mar 2026: earnings 12 Mar to watch

ByHuzaifa Zahoor March 10, 2026March 10, 2026

LGVN stock surged 97.64% intraday to $0.9558 on 10 Mar 2026 as traders priced in near-term news ahead of Longeveron Inc.’s earnings report scheduled for 12 Mar 2026. The move lifted volume to 201,918,348 shares versus an average of 346,000, signaling heavy retail and speculative flow. Investors will watch clinical updates and cash runway metrics in the report, since Longeveron (NASDAQ) is a small-cap biotechnology company with negative EPS and high volatility.